ReviewDrug delivery2023
Advance in placenta drug delivery: concern for placenta-originated disease therapy.
Review in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Placenta-oriented self-assembled Aspirin-RGDV nanoconjugates attenuate preeclampsia through restoration of angiogenic balance.International journal of pharmaceutics: X · 2026Article
- The Self-amplifying Inflammatory Cascade in Obstetric Antiphospholipid Syndrome: From Pathophysiology to Placenta-centric Immunotherapeutic Targets.Clinical reviews in allergy & immunology · 2026Review
- Preliminary Toxicological Evaluation of Spherical Nanoparticles Containing an Imidazole Derivative (BzIm-DEA) Using the CAM Chicken Model.International journal of molecular sciences · 2026Article
- Multi-omics insights into immune tolerance at the maternal-fetal interface in recurrent pregnancy loss: mechanisms, integration challenges, and translational perspectives.Frontiers in immunology · 2026Review
- Three-Dimensionally Printed Paediatric Medicines: Formulation, Process, and Regulatory Considerations.Pharmaceutics · 2025Review
- Nanotechnology in placental cancers: advances in targeted therapy and non-invasive diagnostics.Medical oncology (Northwood, London, England) · 2025Review
- Cost-optimized placenta-targeted nanoparticle for localized immune cloaking in recurrent pregnancy loss.Reproduction & fertility · 2025Article
- A pilot study on LC-MS/MS quantification of remifentanil, etomidate, and rocuronium in maternal and fetal serum microsamples.Scientific reports · 2025Article
- Amniotic fluid-derived stem cells: potential factories of natural and mimetic strategies for congenital malformations.Stem cell research & therapy · 2024Article
- The Application of Nano Drug Delivery Systems in Female Upper Genital Tract Disorders.Pharmaceutics · 2024Review
- Actively Targeted Nanomedicines: A New Perspective for the Treatment of Pregnancy-Related Diseases.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- Fetus Exposure to Drugs and Chemicals: A Holistic Overview on the Assessment of Their Transport and Metabolism across the Human Placental Barrier.Diseases (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the therapy of placenta-originated diseases during pregnancy, the main challenges are fetal exposure to drugs, which can pass through the placenta and cause safety concerns for fetal development. The design of placenta-resident drug delivery system is an advantageous method to minimize fetal exposure as well as reduce adverse maternal off-target effects. By utilizing the placenta as a biological barrier, the placenta-resident nanodrugs could be trapped in the local placenta to concentrate on the treatment of this abnormal originated tissue. Therefore, the success of such systems largely depends on the placental retention capacity. This paper expounds on the transport mechanism of nanodrugs in the placenta, analyzes the factors that affect the placental retention of nanodrugs, and summarizes the advantages and concerns of current nanoplatforms in the treatment of placenta-originated diseases. In general, this review aims to provide a theoretical basis for the construction of placenta-resident drug delivery systems, which will potentially enable safe and efficient clinical treatment for placenta-originated diseases in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.